07.06.26 -- Overcoming The Hurdles Of Cell And Gene Therapy Commercialization

To keep pace with surging GLP-1 demand, pharma needs partners that can rapidly scale injectable production while maintaining flexibility, quality, and regulatory rigor.

Discover how an advanced cell line development platform now supports HEK cells alongside CHO, enabling rapid, scalable production of biologics while saving up to 12 weeks on development timelines.

Reducing biologics costs requires strategic late-stage process development, yield optimization, scale-up, and raw material substitution—all while maintaining product quality and compliance.

Explore a unique model to predict injection force designed to decorrelate factors linked to formulation development and the ones linked to container and delivery device selection.

Find out how reducing vendor fragmentation can improve program continuity, minimize delays, and support more predictable development outcomes.

Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.

Modern drug manufacturing requires a shift toward partnerships that prioritize agility and quality. Success depends on specialized expertise and technical collaboration to navigate requirements.

The post-manufacturing backend of sterile injectable fill-finish operates in a strict sequence—encompassing inspection, testing, QA review, and complex labeling validation—requiring early planning.

Assimilate how biopharma labs are cutting animal use, energy, and paper waste while maintaining GMP compliance — with specific data on 85% labor reductions and 1 ton of CO2e saved annually.

A technical overview of minimizing product loss in aseptic fill‑finish processes, highlighting key loss points and practical strategies to improve yield, efficiency, and manufacturing consistency.

An experienced industry leader shares insights on how biosimilars are reshaping healthcare through scale, manufacturing discipline, supply reliability, and long‑term commercial strategy.

Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.

Review this end-to-end workflow, including First-to-Human antibody development strategies, the use of this platform for targeted immunization, and the precision of single B cell screening.